MI3 Market Alert: New Cleancare hand sanitizer product for US and Canadian against COVID-19
Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on Relevium Technologies Inc. (TSXV: RLV | OTCQB: RLLVF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on Relevium Technologies Inc.
- Relevium operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis.
- Relevium to commercialize BIOGANIX cleancare hand sanitizer from Florida manufacturing partner to supply US and Canada
- RLV surge in Volume and price …
- the stock traded over 62 million shares between $0.015 & $0.07 over the last three session
- Support: S2; $0.045 S1; $0.055 Resistance: R1; $0.075 R2; $0.09
About Relevium Technologies
Relevium is a publicly traded Company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical Company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
PLEASE DO YOUR DUE DILIGENCE
Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.